Stanley Lewis, MD MPH is a graduate of the University of Texas McGovern Medical School and the University of Texas School of Public Health. He completed an Internal Medicine residency and fellowship and joined the faculty as Assistant Professor of Medicine. Dr. Lewis has dedicated his professional career to patient care, teaching, clinical research, and drug development. His areas of interest are infectious disease, oncology, and metabolic disorders. He has participated as an Investigator on over 30 clinical trials and authored over 50 scientific abstracts and publications. Dr. Lewis served as Chief Medical Officer at both public and private biotechnology companies including TaiMed Biologics where he led a small team to develop the first monoclonal antibody for treatment of multi-drug resistant HIV disease. He later Founded and serves as CEO of A28 Therapeutics where he is developing a targeted lytic peptide for treatment of cancer.
